Posts in tag

PBS


Review provides evidence of positive impact of the government’s minimum stockholding requirements policy after 24 months  Improvements are being seen in the rates of medicine shortages and the length of time designated brands …

Pharmacy owners urged to monitor stocks of two medicines that are among the top 50 PBS brands by highest cost to the government, ahead of price changes on 1 February 2026  The Pharmacy Guild …

Covid antivirals lead in top 10 list of subsidised drugs dispensed in RACFs, by highest cost to government Around 14.5 million PBS prescriptions were dispensed in residential aged care facilities …

Semaglutide, apixaban feature on list of top PBS drugs by highest government cost in 2024-25 The Department of Health has released its list of the top 50 PBS drugs by …

How much did the government spend on supply of medicines in 2024-25 compared to the previous year? Government report reveals all Government expenditure was $19.1 billion for the supply of …

Vyvanse sponsor “committed to ensuring pharmacies are not out of pocket”, after $50 PBS price cut  Pharmacies have until 31 December to submit claims for a $55 per unit rebate for …

PBS listing of the combination medicine has led to improved quality of life for patients with cystic fibrosis (CF), says drug utilisation committee Nearly 90% of Australians prescriptions of cystic …

What is the cost and utilisation of the inhaler therapies market? Drug utilisation sub-committee investigates the numbers A PBS committee has considered whether reversion to Authority Required (telephone/online) may be …

A leading economist has queried the sustainability of current levels of government support for pharmacy in a changing financial landscape Government support for pharmacy has helped to keep a lid …

“Particular issues” will need to be addressed before pharmacists are given the green light to prescribe subsidised medicines, a Department official says  Pharmacists could be authorised to prescribe medicines subsidised …

Giving Australians access to new medical technologies within 60 days of TGA registration could help the local economy, Medicines Australia says Shorter listing wait times for new and innovative drugs …

Reimbursement terms make PBS listing “unviable” for eczema treatment, manufacturer claims  Eli Lilly will not proceed with plans to have its targeted IL-13 inhibitor, Ebglyss (lebrikizumab), listed on the Pharmaceutical …